Samyuktha Suresh

Paris, 75005, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

A triple-punch approach: methionine restriction enhances combination inhibitors in brain metastatic triple-negative breast cancer.

A triple-punch approach: methionine restriction enhances combination inhibitors in brain metastatic triple-negative breast cancer.

Journal: The Journal of clinical investigation

Published: July 01, 2025

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells.

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells.

Journal: Scientific reports

Published: June 23, 2025

Small-molecule activator of SMUG1 enhances repair of pyrimidine lesions in DNA.

Small-molecule activator of SMUG1 enhances repair of pyrimidine lesions in DNA.

Journal: DNA repair

Published: August 07, 2024

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.

Journal: Breast cancer (Dove Medical Press)

Published: July 13, 2023

Expression, Localization and Prognosis Association of MEP50 in Breast Cancer.

Expression, Localization and Prognosis Association of MEP50 in Breast Cancer.

Journal: Cancers

Published: September 02, 2022

PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer.

PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer.

Journal: Cancers

Published: December 13, 2021

CARM1/PRMT4: Making Its Mark beyond Its Function as a Transcriptional Coactivator.

CARM1/PRMT4: Making Its Mark beyond Its Function as a Transcriptional Coactivator.

Journal: Trends in cell biology

Published: September 16, 2020

Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.

Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.

Journal: Cancer medicine

Published: December 14, 2018

Showing 1-8 of 8

Last Updated: 09/26/2026